Date Posted:


Zeus Capital advises 4D pharma on its £30m fundraise

8th December 2015

Zeus Capital has advised 4D pharma (DDDD) on its recent £30m fundraise and has now helped the company raise over £100m following a successful flotation on AIM in February 2014 raising £16.5m, with secondary fundraises of £21.5m in July 2014 and £34.8m in January 2015. Zeus Capital is the Company’s Nominated Adviser and was financial adviser and sole broker on all of these transactions.

The Manchester based pharmaceutical company focusing on the development of live biotherapeutics, a new and emerging regulated class of therapeutics, achieved its most recent fundraising at a share price of £7.95 giving it a market capitalisation in excess of £500m with a share price of almost eight times that of the float price.

The company has focused its current interests solely in the microbiome field and the discovery and development of bacteria as live biotherapeutics. The board believes that this field, which is a new class of therapeutics, could deliver a significant step forward in the healthcare market, developing medicines that show greatly improved efficacy and safety profile.

Dan Bate, Corporate Finance Director at Zeus Capital commented:

“We are delighted to have been able to help 4D Pharma with its further fundraising as it continues to develop and broaden its work in the microbiome field. This is an exciting time for the company and we look forward to seeing the continued progress of its expanding pipeline of live biotherapeutics.”

Duncan Peyton, Chief Executive Officer of 4D commented:

“We are pleased to have raised additional funds, and thank the investors for giving the Company both the confidence and capital to continue its rapid development.  Over the last 12 months we have shown the capability not only to take live biotherapeutics into patients, but the ability to rapidly identify and develop new therapeutics that are ready for testing in patients across new disease areas in an incredibly short period of time.  Over the next 12 months we again look to further advance live biotherapeutics and continue to build on our class leading platform”